@article{TCR20301,
author = {David C. Binder and Erik Ladomersky and Alicia Lenzen and Lijie Zhai and Kristen L. Lauing and Sebastian D. Otto-Meyer and Rimas V. Lukas and Derek A. Wainwright},
title = {Lessons learned from rindopepimut treatment in patients with EGFRvIII-expressing glioblastoma},
journal = {Translational Cancer Research},
volume = {7},
number = {Suppl 4},
year = {2018},
keywords = {},
abstract = {EGFRvIII is the most common mutation of EGFR and results in the creation of a tumor-specific antigen that is detectable in 23–33% of human glioblastoma (GBM) (1). EGFRvIII arises due to the deletion of EGFR exons 2–7, which generates a truncated extracellular domain capable of constitutive EGFR activation.},
issn = {2219-6803}, url = {https://tcr.amegroups.org/article/view/20301}
}